SEC Tracker
Get the app

Bambusa Therapeutics BBTX

Salvia Investment GmbH (10% owner) bought 375,000 BBTX at $16.00, worth $6M

Form
4
Filed
Importance
Major
  1. Salvia Investment GmbH acquired 4,769,701 common shares
  2. Salvia Investment GmbH acquired 375,000 common shares at $16 each
  3. Preferred shares converted to 4,769,701 common shares

Written from the Form 4 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Bambusa Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

0 of 1 claim matched the filing text.

Not found in the filing text

  • Bambusa Therapeutics, Inc. filed a Form 4 on November 2, 2026 (accession 0002162499-26-000004).

Similar companies

Same SIC code (2836) and public float not reported.

  1. Adaptimmune Therapeutics ADAP
  2. Adverum Biotechnologies ADVM
  3. AgomAb Therapeutics AGMB
  4. Alvotech ALVO
  5. Argenx ARGX